CTLA4 and melanoma: Targeting CXCR2 has been shown to significantly reduce NET formation in melanoma, and inhibition of NET formation has been observed to enhance tumor sensitivity to double checkpoint blockade using PD-1 and CTLA-4 inhibitors (51).